Ontvang nu dagelijks onze kooptips!

word abonnee
IEX 25 jaar
Uitgebreid zoeken

Beurscodes, betekenis en hulp bij zoeken

Europa

AEX
Euronext Amsterdam
BRU
Euronext Brussels
PSE
Euronext Paris
LIS
Euronext Lissabon
CHX
CBOE Europe, grote(re) EU aandelen
NAV
Investment Funds (NAV)

Noord-Amerika

NYS
New York Stock Exchange
OTC
CBOE BZX Exchange (US)
TSE
Toronto Stock Exchange

Kunt u een instrument niet vinden?

Zoek dan via de zogenaamde ISIN code. Elk instrument, aandeel etc. heeft een unieke code.

Kies vervolgens - wanneer er meerdere resultaten zijn - de notering op de beurs van uw keuze.

Waar vind ik die ISIN code?

Google de naam van het instrument, aandeel etc. met de toevoeging 'ISIN'.

Als zoeken op ISIN code geen resultaten oplevert hebben wij het instrument of aandeel niet in onze koersendatabase.

desktop iconMarkt Monitor
Markt vandaag Koersen Forum Premium IEX Expert
Home  /   Forum   /   BioPharma   /   HZNP

BioPharma« Terug naar discussie overzicht

HZNP

Volgen
70 Posts
Pagina: «« 1 2 3 4 »» | Laatste | Omlaag ↓
  2. gustaaf1e 19 maart 2013 20:12
    Zonder commentaar. De resultaten en de ontwikkeling daarvan in 2012 spreken namelijk voor zichzelf.
    G

    DEERFIELD, IL -- (Marketwire) -- 03/18/13 -- Horizon Pharma, Inc. (NASDAQ: HZNP) today provided an update on the Company's business and announced financial results for the fourth quarter and year ended December 31, 2012.

    Financial Highlights
    •Full year 2012 gross and net sales were $23.0 million and $19.6 million, respectively; increases of 231% and 183%, respectively, over full year 2011 gross and net sales.
    •Fourth quarter 2012 gross and net sales were $8.2 million and $6.7 million, respectively; increases of 130% and 91%, respectively, over fourth quarter 2011 gross and net sales.
    •Net loss for 2012 was $87.8 million, or $2.26 per share, compared to a net loss of $113.3 million, or $12.56 per share, in 2011.
    •Cash and cash equivalents balance at the end of 2012 was $104.1 million, which the Company believes will be sufficient to fund its operations through 2013.

    DUEXIS® Highlights
    •New prescriptions for DUEXIS increased 57% in the fourth quarter of 2012 to 31,130 versus 19,874 in the third quarter of 2012.
    •Total prescriptions for DUEXIS increased 56% in the fourth quarter of 2012 to 39,060 versus 25,054 in the third quarter of 2012.
    •DUEXIS gross and net sales were $13.2 million and $11.0 million, respectively, in 2012, which was the first full year of sales following the launch of DUEXIS in December 2011.
    •DUEXIS fourth quarter 2012 gross and net sales were $7.1 million and $6.0 million, respectively; increases of 138% and 132%, respectively, over third quarter 2012 DUEXIS gross and net sales. Excluding a one-time increase in fourth quarter 2012 DUEXIS sales related to timing of revenue recognition, sequential growth from the third quarter of 2012 to the fourth quarter of 2012 in both gross and net sales was 76%.

    RAYOS® Highlights
    •Initiated full commercial launch of RAYOS to rheumatologists and key primary care physicians through 150-person sales force in February 2013.
    •There have been 275 cumulative RAYOS prescribers since the launch.

    "We saw strong momentum with DUEXIS in the fourth quarter of 2012 and early 2013, which along with the full commercial launch of RAYOS last month, positions us well moving forward," said Timothy P. Walbert, chairman, president and chief executive officer, Horizon Pharma. "With two products commercialized in the U.S. market and $104.1 million in cash on the balance sheet, we are encouraged by our progress as we continue to build towards our objective of a profitable, sustainable business."

  13. gustaaf1e 20 november 2013 10:12
    Dank Junkbond,
    De toekomst van dit bedrijf ziet er rooskleurig uit.
    HZNP is door deze transactie met AZ en door de stevige vorderingen met de verkoop van beide goedgekeurde produkten veel sneller winstgevend dan eerder gedacht. Bovendien komt er ook daardoor veel sneller financiele ruimte voor nieuwe verwervingen die in hun bestaande verkoopkanalen (die dus maar weinig extra geld kosten) kunnen worden meegenomen. De verkoopkanalen worden met een goedkope lening verder uitgebreid.
    Ik verwacht dat de komende weken de koersdoelen verder naar boven zullen worden bijgesteld.
    G
  16. gustaaf1e 18 december 2013 09:27

    December 17, 2013

    Horizon Pharma to Be Added to NASDAQ Biotechnology Index

    DEERFIELD, IL -- (Marketwired) -- 12/17/13 -- Horizon Pharma, Inc. (NASDAQ: HZNP), today announced that it has been selected for addition to the NASDAQ Biotechnology Index effective prior to the market open on Monday, December 23, 2013.

    G
70 Posts
Pagina: «« 1 2 3 4 »» | Laatste |Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord.

Direct naar Forum

Markt Vandaag

Stijgers

instrument koers absoluut verschil relatief verschil
EBUSCO HOLDING 0,938 +0,07 +8,01%
Brunel 8,670 +0,32 +3,83%
PostNL 1,041 +0,03 +3,07%
AZERION 1,180 +0,03 +2,61%
Pharming 0,723 +0,02 +2,48%
HEIJMANS KON 28,000 +0,50 +1,82%
THEON INTERNAT 10,400 +0,18 +1,76%
Sif Holding 12,160 +0,20 +1,67%
ALLFUNDS GROUP 5,405 +0,09 +1,60%
CTP 15,100 +0,22 +1,48%
Galapagos 26,220 +0,38 +1,47%
OCI 11,180 +0,14 +1,22%
FASTNED 21,400 +0,25 +1,18%
JDE PEET'S 18,950 +0,19 +1,01%
NX FILTRATION 4,105 +0,04 +0,98%
Aperam 26,960 +0,26 +0,97%
Alfen N.V. 11,660 +0,11 +0,95%
Ahold Delhaize 32,830 +0,30 +0,92%
UMG 22,700 +0,20 +0,89%
Eurocommercial Properties 23,400 +0,20 +0,86%
UNILEVER PLC 56,640 +0,46 +0,82%
Nedap N.V. 53,000 +0,40 +0,76%
Van Lanschot Kempen NV 42,300 +0,30 +0,71%
ACOMO 17,400 +0,12 +0,69%
INPOST 17,580 +0,12 +0,69%
ASCX 1.173,43 +7,38 +0,63%
NSI 19,620 +0,12 +0,62%
KPN 3,663 +0,02 +0,60%
Wereldhave 13,940 +0,08 +0,58%
RANDSTAD NV 41,230 +0,23 +0,56%
Akzo Nobel 55,320 +0,30 +0,55%
Flow Traders 21,120 +0,10 +0,48%
WDP 20,640 +0,08 +0,39%
Heineken 69,980 +0,26 +0,37%
RELX 44,720 +0,16 +0,36%
Aegon 5,910 +0,02 +0,34%
ArcelorMittal 23,060 +0,07 +0,30%
AALBERTS NV 34,000 +0,10 +0,29%
PROSUS 38,095 +0,09 +0,22%
Wolters Kluwer 157,700 +0,35 +0,22%
Vastned 24,450 +0,05 +0,20%
Philips Koninklijke 25,810 +0,05 +0,19%
Fagron 18,580 +0,02 +0,11%
AMX 862,05 +0,36 +0,04%
ING 14,438 0,00 0,00%
TKH 30,860 0,00 0,00%

Dalers

instrument koers absoluut verschil relatief verschil
AMG Critical Materials N.V. 14,310 -0,48 -3,25%
Air France-KLM 7,276 -0,21 -2,81%
Accsys 0,571 -0,02 -2,56%
CM.COM 5,820 -0,15 -2,51%
JUST EAT TAKEAWAY 14,500 -0,35 -2,36%
BESI 108,600 -2,30 -2,07%
ASMI 493,200 -10,00 -1,99%
B&S Group SA 4,315 -0,05 -1,26%
ASML 632,300 -7,70 -1,20%
SIGNIFY NV 20,760 -0,24 -1,14%
ForFarmers 3,205 -0,04 -1,08%
RENEWI 6,730 -0,06 -0,88%
Kendrion 10,660 -0,08 -0,74%
Avantium 2,120 -0,01 -0,70%
TomTom 5,220 -0,03 -0,57%
Basic-Fit 21,200 -0,12 -0,56%
ASR Nederland 44,390 -0,25 -0,56%
ADYEN NV 1.378,600 -6,60 -0,48%
SHELL PLC 30,740 -0,14 -0,44%
SBM Offshore 17,060 -0,07 -0,41%
BAM 3,904 -0,02 -0,41%
NN Group 43,740 -0,16 -0,36%
IMCD 138,950 -0,50 -0,36%
Fugro 16,750 -0,05 -0,30%
DSM FIRMENICH AG 104,600 -0,30 -0,29%
Arcadis 62,150 -0,15 -0,24%
Vopak 44,060 -0,10 -0,23%
ABN AMRO BANK N.V. 14,565 -0,03 -0,21%
Sligro 10,780 -0,02 -0,19%
AEX 874,19 -0,95 -0,11%
EXOR NV 93,800 -0,10 -0,11%
Corbion 21,700 -0,02 -0,09%
vlag naam koers verschil relatief verschil
AEX 873,55 -1,59 -0,18%
AEX GR 3.431,45 -1,14 -0,03%
Germany40^ 19.237,80 -58,18 -0,30%
FTSE 100 8.270,13 +11,52 +0,14%
EURO50 4.731,91 -27,01 -0,57%
US30^ 44.936,90 +87,10 +0,19%
Nasd100^ 20.683,60 -239,80 -1,15%
US500^ 6.002,06 -20,10 -0,33%
Japan225^ 37.931,70 -401,50 -1,05%
VD-NEW 15,60 +0,26 +1,69%
#/^ Index indications calculated real time, zie disclaimer